Pillar Guide
Peptide Therapy: Complete Guide to Physician-Supervised Peptides
GLP-1, growth-hormone peptides, regenerative peptides — explained by a physician.
The short answer: Peptide therapy is the use of short amino-acid chains as targeted signaling molecules — distinct from full hormones or small-molecule drugs. The most evidence-supported peptides in 2026 are the GLP-1 agonists (semaglutide, tirzepatide) for weight and metabolic care, sermorelin and CJC-1295/ipamorelin for growth-hormone optimization, BPC-157 for tissue regeneration, and PT-141 for libido. All require physician evaluation, lab work, and ongoing supervision.
Comparison table — peptide, category, evidence, route
| Peptide | Category | Evidence | Route |
|---|---|---|---|
| Semaglutide | GLP-1 agonist | FDA-approved | Weekly subcutaneous |
| Tirzepatide | Dual GIP/GLP-1 agonist | FDA-approved | Weekly subcutaneous |
| Retatrutide | Triple agonist (GIP/GLP-1/glucagon) | Phase 3 trials | Weekly subcutaneous |
| Sermorelin | Growth hormone-releasing peptide | Off-label, decades of use | Daily subcutaneous |
| CJC-1295 + Ipamorelin | GHRH analog + ghrelin mimetic | Off-label compounded | Daily subcutaneous |
| BPC-157 | Pentadecapeptide (regenerative) | Animal + early clinical | Oral or subcutaneous |
| PT-141 (Bremelanotide) | Melanocortin agonist | FDA-approved (HSDD) | Subcutaneous as needed |
| AOD-9604 | GH fragment 176-191 | Early clinical | Daily subcutaneous |
| GHK-Cu | Copper-peptide complex | Topical: strong; systemic: limited | Topical or subcutaneous |
What is Semaglutide?
Semaglutide is a GLP-1 receptor agonist FDA-approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). It slows gastric emptying, reduces appetite, and produces 12–15% average body-weight loss over 68 weeks in clinical trials. Compounded semaglutide expands access while branded supply is constrained; kindr Health prescribes both branded and compounded forms after physician evaluation.
What is Tirzepatide?
Tirzepatide is a dual GIP and GLP-1 receptor agonist FDA-approved as Mounjaro (diabetes) and Zepbound (weight). The dual mechanism produces higher average weight loss than semaglutide — roughly 20% at 72 weeks at the 15 mg dose — with a similar gastrointestinal side-effect profile.
What is Retatrutide?
Retatrutide is an investigational triple agonist showing the largest weight-loss results to date — up to 24% in Phase 2 trials. Not yet FDA-approved; kindr Health does not prescribe retatrutide. This page is informational while approval is pending.
What is Sermorelin?
Sermorelin stimulates the pituitary to release endogenous growth hormone in a physiological pulsatile pattern. Used off-label for body-composition support, recovery, and sleep quality in adults over 35 with documented GH decline.
What is CJC-1295 + Ipamorelin?
A combination of a long-acting GHRH analog (CJC-1295) and a selective growth hormone secretagogue (ipamorelin). Produces larger GH release than sermorelin without significantly raising cortisol or prolactin.
What is BPC-157?
BPC-157 is a 15-amino-acid fragment derived from gastric juice with strong preclinical data for tendon, ligament, gut, and vascular healing. Human clinical data is early-stage; use is off-label.
What is PT-141 (Bremelanotide)?
PT-141 (bremelanotide) is a melanocortin receptor agonist FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women. Used off-label in postmenopausal women and men for libido support.
What is AOD-9604?
AOD-9604 is a modified C-terminal fragment of growth hormone studied for fat metabolism without GH’s growth or insulin effects. Clinical evidence is mixed; positioned as adjunctive only.
What is GHK-Cu?
GHK-Cu is a tripeptide-copper complex with extensive cosmetic-dermatology evidence for skin remodeling and hair-follicle support. Subcutaneous use is off-label and less well-studied.
Who is eligible for peptide therapy?
Adults 18 and older with a clinical indication after physician evaluation. Pre-prescription requirements at Kindr Health: a brief medical history, baseline labs appropriate to the peptide (CBC, CMP, lipid panel, A1c, IGF-1 for GH peptides), and an asynchronous or synchronous physician consultation. Pregnancy, active malignancy, and uncontrolled endocrine disease are contraindications for most peptides.
Frequently asked questions
Are peptide therapies FDA-approved?
Some — semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound), and bremelanotide (Vyleesi) are FDA-approved. Sermorelin was previously approved for pediatric GH deficiency. CJC-1295, ipamorelin, BPC-157, AOD-9604, and GHK-Cu are used off-label and dispensed via compounding pharmacies under physician supervision.
How is peptide therapy delivered?
Most peptides are dispensed as subcutaneous injections in small-volume vials with insulin syringes. Some (PT-141, BPC-157 oral) have alternative routes. Every kindr Health peptide order ships with full instructions and a physician-supervised onboarding.
Who is a candidate for peptide therapy?
Adults 18+ with clear clinical indication after physician evaluation. Pregnancy, active cancer, and certain endocrine conditions are contraindications. A kindr Health clinician reviews labs and history before any prescription is issued.
How long until peptides work?
GLP-1 weight loss begins in 2–4 weeks. Sermorelin and CJC/Ipamorelin sleep effects appear in 1–2 weeks; body-composition changes take 3–6 months. BPC-157 tissue-healing effects are typically measured at 4–8 weeks. PT-141 acts within hours of injection.
Are peptides safe to combine with HRT?
Generally yes. GLP-1s, sermorelin, CJC/Ipamorelin, and BPC-157 do not have clinically meaningful interactions with estradiol, progesterone, or testosterone. A kindr Health physician reviews the full medication list before prescribing.
How much does peptide therapy cost?
Compounded semaglutide and tirzepatide programs start around $199–$399/month; growth-hormone peptides $250–$500/month; PT-141 priced per dose. kindr Health publishes transparent pricing on every product page.
Medically reviewed by Dr. Ana Lisa Carr, MD, MBA, board-certified Family Medicine physician (NPI 1689841744). Last reviewed 2026-06-10. All peptide prescriptions require physician evaluation and ongoing monitoring at Kindr Health.
Latest from the Journal
Weight & metabolism
HRT vs GLP-1 for menopause weight loss: which is right for you?
Hormone therapy addresses the hormonal causes of midlife weight gain. GLP-1s like semaglutide target appetite and metabolism. Here is how they differ — and when to use one, the other, or both.
Read HRT vs GLP-1 for menopause weight loss: which is right for you? →
Lifestyle
Strength training in menopause: the single most important habit after 40
Estrogen loss accelerates muscle and bone decline. Resistance training — done correctly — is the closest thing we have to a medication for it.
Read Strength training in menopause: the single most important habit after 40 →
Perimenopause
Understanding perimenopause: the years before menopause
Perimenopause can begin in your late 30s or 40s and last up to a decade. Here is what is happening hormonally and what actually helps.
Read Understanding perimenopause: the years before menopause →